Ardelyx, Inc. to Host Conference Call for 2025 Financial Results and Business Update

Ardelyx will host a conference call on February 19, 2026, to discuss financial results and business updates.

Quiver AI Summary

Ardelyx, Inc., a biopharmaceutical company focused on developing innovative medicines, has announced a conference call scheduled for February 19, 2026, at 4:30 p.m. Eastern Time. During the call, the company's executive leadership, including CEO Mike Raab and CFO Sue Hohenleitner, will discuss the financial results and business updates for the full year and fourth quarter of 2025. Interested parties can participate by calling designated numbers or by listening to a live webcast available on the company's website, with an archive for replay for 30 days. Ardelyx offers two commercial products in the U.S. and is advancing its drug pipeline, including evaluating IBSRELA for chronic idiopathic constipation and developing a next-generation NHE3 inhibitor.

Potential Positives

The upcoming conference call indicates that Ardelyx is proactively engaging with investors and stakeholders to discuss financial results and business updates, highlighting transparency.
The presence of key executives on the call may instill confidence in investors, demonstrating strong leadership commitment and expertise.
Ardelyx’s two approved commercial products and ongoing clinical developments suggest a robust pipeline and growth potential in the biopharmaceutical market.
The international partnerships and product approvals in multiple countries signify Ardelyx’s expanding global presence and market opportunities.

Potential Negatives

Announcement about an upcoming conference call may indicate that the company's financial results could reveal concerns or disappointing performance, leading to speculation regarding its financial health.
Limited information presented about the company's current financial status or product pipeline may raise questions among investors about the company's future prospects and clarity on ongoing challenges.
Dependence on external partnerships for product commercialization, such as those in Japan and Canada, may raise concerns about the company's ability to penetrate and capture markets independently.

FAQ

When is Ardelyx's next conference call?

Ardelyx's next conference call is scheduled for February 19, 2026, at 4:30 p.m. Eastern Time.

Who will speak during the conference call?

The call will feature commentary from key executives including Mike Raab, Sue Hohenleitner, Eric Foster, and Laura Williams.

How can I participate in the Ardelyx conference call?

To participate, dial (877) 346-6112 for domestic or (848) 280-6350 for international access.

Will the conference call be available for replay?

Yes, the webcast will be archived and available for replay for 30 days after the call.

What are some products developed by Ardelyx?

Ardelyx has two approved products: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor), targeting various medical needs.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$ARDX Insider Trading Activity

$ARDX insiders have traded $ARDX stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.

Here’s a breakdown of recent trading of $ARDX stock by insiders over the last 6 months:

LAURA A WILLIAMS (Chief Patient Officer) has made 0 purchases and 5 sales selling 142,687 shares for an estimated $911,298.
MICHAEL RAAB (President & CEO) has made 0 purchases and 2 sales selling 92,574 shares for an estimated $530,610.
ERIC DUANE FOSTER (Chief Commercial Officer) has made 0 purchases and 2 sales selling 21,122 shares for an estimated $122,994.
ELIZABETH A GRAMMER (See Remarks) has made 0 purchases and 2 sales selling 11,836 shares for an estimated $67,840.
MIKE KELLIHER (See Remarks) has made 0 purchases and 2 sales selling 10,977 shares for an estimated $62,917.
JOSEPH JAMES REILLY (See Remarks) sold 11,086 shares for an estimated $61,382
JUSTIN A RENZ (Chief Financial Officer) sold 7,037 shares for an estimated $41,741

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$ARDX Hedge Fund Activity

We have seen 113 institutional investors add shares of $ARDX stock to their portfolio, and 99 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MILLENNIUM MANAGEMENT LLC removed 4,021,242 shares (-34.5%) from their portfolio in Q3 2025, for an estimated $22,157,043
BANK OF AMERICA CORP /DE/ removed 2,873,791 shares (-52.0%) from their portfolio in Q3 2025, for an estimated $15,834,588
MARSHALL WACE, LLP removed 2,307,610 shares (-20.5%) from their portfolio in Q3 2025, for an estimated $12,714,931
NUVEEN, LLC added 1,685,009 shares (+48.3%) to their portfolio in Q3 2025, for an estimated $9,284,399
TWO SEAS CAPITAL LP removed 1,539,416 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $8,482,182
EVERSEPT PARTNERS, LP added 1,429,377 shares (+inf%) to their portfolio in Q3 2025, for an estimated $7,875,867
JANE STREET GROUP, LLC added 1,425,533 shares (+185.6%) to their portfolio in Q3 2025, for an estimated $7,854,686

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ARDX Analyst Ratings

Wall Street analysts have issued reports on $ARDX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 01/29/2026
Wedbush issued a "Outperform" rating on 01/21/2026
Citigroup issued a "Buy" rating on 11/03/2025
TD Cowen issued a "Buy" rating on 10/31/2025

To track analyst ratings and price targets for $ARDX, check out Quiver Quantitative's $ARDX forecast page.

$ARDX Price Targets

Multiple analysts have issued price targets for $ARDX recently. We have seen 5 analysts offer price targets for $ARDX in the last 6 months, with a median target of $16.0.

Here are some recent targets:

Julian Harrison from BTIG set a target price of $17.0 on 01/29/2026
Laura Chico from Wedbush set a target price of $19.0 on 01/21/2026
Christopher Raymond from Piper Sandler set a target price of $16.0 on 01/09/2026
Yigal Nochomovitz from Citigroup set a target price of $14.0 on 01/09/2026
Joseph Thome from TD Cowen set a target price of $10.0 on 10/31/2025

Full Release

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 19, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2025. The call will include commentary from members of the Ardelyx Executive Leadership Team including Mike Raab, President and Chief Executive Officer, Sue Hohenleitner, Chief Financial Officer, Eric Foster, Chief Commercial Officer, and Laura Williams M.D., M.P.H., Chief Patient Officer and Interim Chief Medical Officer.

To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com . The webcast will be archived and available for replay for 30 days following the call.

About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA ^® (tenapanor) and XPHOZAH ^® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL ^® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter) , LinkedIn and Facebook .

Investor and Media Contacts:
Caitlin Lowie
[email protected]